FERRARI, Roberto
 Distribuzione geografica
Continente #
NA - Nord America 57.282
AS - Asia 27.772
EU - Europa 21.990
SA - Sud America 4.600
Continente sconosciuto - Info sul continente non disponibili 1.017
AF - Africa 608
OC - Oceania 81
AN - Antartide 2
Totale 113.352
Nazione #
US - Stati Uniti d'America 56.041
SG - Singapore 10.403
FI - Finlandia 6.703
CN - Cina 6.680
IT - Italia 4.742
BR - Brasile 3.515
VN - Vietnam 2.741
UA - Ucraina 2.509
HK - Hong Kong 2.450
DE - Germania 2.169
TR - Turchia 1.624
GB - Regno Unito 1.475
BD - Bangladesh 979
FR - Francia 968
SE - Svezia 816
RU - Federazione Russa 726
PL - Polonia 665
JP - Giappone 633
IN - India 551
CA - Canada 549
MX - Messico 423
ID - Indonesia 361
AR - Argentina 357
NL - Olanda 239
IQ - Iraq 220
ZA - Sudafrica 198
EC - Ecuador 184
CO - Colombia 180
ES - Italia 178
PK - Pakistan 168
BE - Belgio 124
VE - Venezuela 118
AT - Austria 110
PH - Filippine 102
MY - Malesia 100
SA - Arabia Saudita 95
UZ - Uzbekistan 92
MA - Marocco 86
CL - Cile 79
LT - Lituania 72
CZ - Repubblica Ceca 71
IE - Irlanda 69
EG - Egitto 66
PY - Paraguay 66
AU - Australia 64
JM - Giamaica 64
AE - Emirati Arabi Uniti 61
CH - Svizzera 57
TN - Tunisia 55
KE - Kenya 54
KR - Corea 52
JO - Giordania 42
PE - Perù 41
CR - Costa Rica 35
UY - Uruguay 34
TH - Thailandia 32
IL - Israele 30
AL - Albania 29
OM - Oman 29
RO - Romania 28
DZ - Algeria 27
GT - Guatemala 27
KZ - Kazakistan 27
TW - Taiwan 27
ET - Etiopia 25
HN - Honduras 25
IR - Iran 24
NP - Nepal 23
AZ - Azerbaigian 22
BG - Bulgaria 22
GR - Grecia 22
LB - Libano 22
LK - Sri Lanka 22
PT - Portogallo 22
SN - Senegal 22
RS - Serbia 21
GE - Georgia 20
HU - Ungheria 20
TT - Trinidad e Tobago 20
HR - Croazia 19
KG - Kirghizistan 18
PS - Palestinian Territory 18
BO - Bolivia 16
NI - Nicaragua 16
NO - Norvegia 16
NZ - Nuova Zelanda 16
DO - Repubblica Dominicana 14
SV - El Salvador 14
BA - Bosnia-Erzegovina 13
BH - Bahrain 13
KW - Kuwait 13
EU - Europa 12
MD - Moldavia 12
PA - Panama 12
AM - Armenia 10
BY - Bielorussia 10
CI - Costa d'Avorio 10
DK - Danimarca 10
SY - Repubblica araba siriana 10
XK - ???statistics.table.value.countryCode.XK??? 10
Totale 112.126
Città #
Singapore 6.431
Helsinki 6.053
Ashburn 6.020
Fairfield 5.339
Woodbridge 5.002
Houston 3.212
San Jose 3.182
Jacksonville 2.717
Hong Kong 2.403
Chandler 2.390
Seattle 2.136
Ann Arbor 2.106
Santa Clara 1.973
Wilmington 1.881
Beijing 1.839
Cambridge 1.777
Dallas 1.729
Council Bluffs 1.399
Izmir 960
Ho Chi Minh City 896
Nanjing 872
New York 777
Princeton 752
Los Angeles 718
Warsaw 624
Hanoi 615
Tokyo 589
Lauterbourg 550
Milan 499
San Diego 481
Boardman 463
Munich 431
Ferrara 427
São Paulo 327
Shanghai 292
Rome 277
Mexico City 272
Shenyang 264
Nanchang 245
Jakarta 234
Chicago 233
Moscow 219
London 209
Toronto 172
Hefei 169
Tianjin 169
Buffalo 159
Changsha 156
Falls Church 155
Orem 153
Hebei 147
Jiaxing 147
Bologna 146
Phoenix 140
Turku 139
Bremen 136
Redwood City 132
Brooklyn 125
Montreal 124
Rio de Janeiro 122
San Mateo 122
The Dalles 122
Mountain View 119
Dong Ket 118
Naples 117
Brussels 116
Chennai 112
Frankfurt am Main 109
Addison 107
Da Nang 104
Haiphong 103
Johannesburg 103
San Francisco 103
Jinan 101
Atlanta 93
Nuremberg 93
Zhengzhou 93
Tashkent 86
Stockholm 85
Norwalk 82
Columbus 81
Dearborn 81
Baghdad 80
Guangzhou 79
Denver 78
Washington 78
Boston 77
Verona 76
Falkenstein 75
Philadelphia 75
Manchester 74
Quito 69
Belo Horizonte 67
Amsterdam 65
Ningbo 65
Kunming 64
Curitiba 61
Brasília 60
Mumbai 60
Des Moines 57
Totale 75.816
Nome #
1,3,8-Triazaspiro compounds and their use as medicaments for the treatment of reperfusion injury. 2.966
17β-Estradiol Enhances Signalling Mediated by VEGF-A-Delta-Like Ligand 4-Notch1 Axis in Human Endothelial Cells 2.144
A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients 2.064
IL METABOLISMO DEL MIOCARDIO ISCHEMICO IBERNATO E STORDITO: DIFFERENZA TRA NECROSI E APOPTOSI 1.852
Il lungo cammino degli inibitori dell'enzima di conversione dell'angiotensina nella lotta per le malattie cardiovascolari 555
Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and C-ring conformation 437
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD 437
A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial 435
Valutazione ecocardiografica dell'insufficienza mitralica nella prospettiva della riparazione valvolare 413
The Notch pathway: a novel therapeutic target for cardiovascular diseases? 383
Physical activity intervention for elderly patients with reduced physical performance after acute coronary syndrome (HULK study): Rationale and design of a randomized clinical trial 382
Left ventricular ejection fraction and heart failure: an indissoluble marriage? 381
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease 368
Scompenso cardiaco con frazione di eiezione intermedia. Alla ricerca della Terra di Mezzo? 344
Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction 343
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 334
Polar plot maps by parametric strain echocardiography allow accurate evaluation of non-viable transmural scar tissue in ischaemic heart disease 315
Estrogen receptor β-dependent Notch1 activation protects vascular endothelium against tumor necrosis factor α (TNFα)-induced apoptosis 315
Poor response to clopidogrel: current and future options for its management 310
Distinct gene expression profiles associated with Notch ligands Delta-like 4 and Jagged1 in plaque material from peripheral artery disease patients: A pilot study 308
Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study 296
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) 287
Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings 287
Cardiac resynchronization therapy guided by multimodality cardiac imaging 283
Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients 282
2014 ESC guidelines on the diagnosis and treatment of aortic diseases 276
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure 276
2013 ESH/ESC Guidelines for the management of arterial hypertension 276
Demographic and clinical characteristics of patients with stable coronary artery disease: results from the CLARIFY registry in Spain 273
Reperfusion Damage - A Story of Success, Failure, and Hope 271
High-dose BoluS TiRofibAn and Sirolimus eluting STEnt versus abiciximab and bare metal stent in acute MYocardial infarction (STRATEGY) study - Protocol design and demography of the first 100 patients 270
CANCER THERAPY-INDUCED CARDIOTOXICITY: ROLE OF ULTRASOUND DEFORMATION IMAGING AS AN AID TO EARLY DIAGNOSIS 270
Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis 268
A Clinical Case of Catecholaminergic Polymorphic Ventricular Tachycardia: The Clinical Suspicious and the Need of Genetics 268
The role of Notch pathway in cardiovascular diseases. 268
Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis 266
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions 264
Uric acid and coronary artery disease: An elusive link deserving further attention 260
Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients with ST-Segment-Elevation Myocardial Infarction and Multivessel Disease 260
Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review 258
2013 ESC guidelines on the management of stable coronary artery disease 256
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma 254
Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. 253
The assessment of scales of frailty and physical performance improves prediction of major adverse cardiac events in older adults with acute coronary syndrome 252
Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials 251
Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry 251
Aortic valve stenosis and mitochondrial dysfunctions: Clinical and molecular perspectives 250
Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker? 250
Tissue factor and coagulation factor VII levels during acute myocardial infarction: Association with genotype and adverse events 249
Abnormalities of Left Ventricular Function in Asymptomatic Patients with Systemic Sclerosis Using Doppler Measures of Myocardial Strain 249
Grip strength predicts cardiac adverse events in patients with cardiac disorders: An individual patient pooled meta-analysis 249
The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rational and design of a multicenter prospective study 247
Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients 247
KRIT1 deficiency promotes aortic endothelial dysfunction 246
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT) 246
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile 245
ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: Diagnostic-therapeutic pathway in Italy 244
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes 242
2013 ESH/ESC Guidelines for the management of arterial hypertension 242
Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention 241
Efficacy and safety of catheter ablation of atrioventricular nodal re-entrant tachycardia by means of flexible-tip irrigated catheters 241
Effects of temperature on myocardial calcium homeostasis and mitochondrial function during ischemia and reperfusion 238
Mutation Load of Multiple Ion Channel Gene Mutations in Brugada Syndrome 238
Left Ventricular Lead Position Guided by Parametric Strain Echocardiography Improves Response to Cardiac Resynchronization Therapy 238
Attualità e nuove prospettive in tema di cardiogenetica 236
Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study 236
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals 233
Angina and left ventricular dysfunction: can we "reduce' it? 231
181 QUESTIONS & ANSWERS IN HEART FAILURE Heart failure 181 Questions & Answers. 230
Heart failure with preserved ejection fraction: uncertainties and dilemmas 230
Current views on anthracycline cardiotoxicity 229
Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction 228
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes (Am Journal of Cardiovasc Drugs (2011) 11:3 (189-98)) 228
Anti-anginal drugs: Systematic review and clinical implications 227
Nutritional status and all-cause mortality in older adults with acute coronary syndrome 227
Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL 225
Can we improve myocardial protection during ischaemic injury? 225
Effectiveness of a novel nutraceutical compound containing red yeast rice, polymethoxyflavones and antioxidants in the modulation of cholesterol levels in subjects with hypercholesterolemia and low-moderate cardiovascular risk: The NIRVANA study 225
In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry 224
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 223
Current role of echocardiography in cardiac resynchronization therapy 222
FXIII levels and genotypes in myocardial infarction: a potential novel prognostic biomarker? 220
In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome 220
Right Ventricle Function in Patients with Acute Coronary Syndrome and Concomitant Undiagnosed Chronic Obstructive Pulmonary Disease 220
CHA2DS2-VASc score predicts atrial fibrillation recurrence after cardioversion: systematic review and individual patient pooled meta-analysis 218
Assessment of left ventricular volume and function by integration of simplified 3D echocardiography, tissue harmonic imaging and automated extraction of endocardial borders 217
Improved recognition of dysfunctioning myocardial segments by longitudinal strain rate versus velocity in patients with myocardial infarction 214
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study 214
EL PENSAMIENTO NARRATIVO PARA CONTRARRESTAR LAS ENFERMEDADES CARDIOVASCULARES. PRIMEROS RESULTADOS DE UN CAMINO DE PREVENCIÓN SECUNDARIA 214
Prognosis after pacemaker implantation in extreme elderly 214
From left ventricular ejection fraction to cardiac hemodynamics: role of echocardiography in evaluating patients with heart failure 214
99mTc-sestamibi gted -Spect evaluation of post stress left ventricular ejection fraction and volumes in hypertensive patients exhibiting a normal scintigraphic perfusion pattern 213
Kounis-Zavras syndrome presenting with ventricular arrhythmias and cardiogenic shock 213
The role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitors 213
Adding a “Notch” to Cardiovascular Disease Therapeutics: A MicroRNA-Based Approach 213
Acute Coronaric Syndroms and FVII polymorphisms: different effects in the same gene 212
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: An analysis from the SIGNIFY study 212
Short Physical Performance Battery and all-cause mortality: Systematic review and meta-analysis 212
Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry 211
Remote monitoring of implantable devices: Should we continue to ignore it? 210
Totale 34.417
Categoria #
all - tutte 496.605
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 6.610
Totale 503.215


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.970 0 0 577 273 413 357 359 366 296 505 753 2.071
2022/20236.078 715 190 226 668 982 900 219 634 840 60 397 247
2023/20243.481 359 433 210 120 238 490 152 206 77 160 153 883
2024/202512.621 303 307 1.107 466 1.429 1.036 462 840 2.357 1.378 1.541 1.395
2025/202642.642 3.125 1.753 4.140 4.576 4.727 2.266 3.572 2.131 9.331 4.023 1.894 1.104
2026/20274.355 1.211 1.993 1.151 0 0 0 0 0 0 0 0 0
Totale 113.352